Ampoules being flame-sealed on a filling and sealing machine
Finished Dosage Forms (Rx)

Finished Dosage Forms Compliance Services

Coaching for oral solid dose and sterile facilities: 21 CFR 210/211 cGMP, FDA PAI readiness, sterile manufacturing and data integrity (Part 11).

  • Market route first
  • Evidence files aligned
  • Less rework before audits

Finished Dosage Form Compliance Challenges

Rx finished-drug manufacturing faces both FDA cGMP and PAI site inspection; sterile manufacturing and data integrity are high-frequency inspection concerns.

21 CFR 210/211 cGMP

Finished-drug production must meet pharmaceutical-grade cGMP under 21 CFR 210/211 across facilities, equipment, materials, production and laboratory controls.

FDA PAI Readiness

Pre-Approval Inspections (PAI) focus on process validation, data reliability and commercial manufacturing readiness before approval.

Sterile Manufacturing & Annex 1

Sterile products must meet 21 CFR 211 Subpart F and EU GMP Annex 1 requirements for cleanrooms, sterilising filtration, container closure integrity and media fills.

Data Integrity (Part 11)

Electronic records and signatures must meet 21 CFR Part 11, with batch records, testing and audit trails satisfying ALCOA+ data integrity principles.

Related Compliance Support

QTC coaches finished-drug facilities for PAI and buyer GMP audits: gap diagnosis, sterile and data integrity review, and timed 483/Warning Letter response with CAPA closure.

FDA 483 / Warning Letter Response Workflow (6 Steps + 15 Business Days)

Staged

For finished-drug facilities that received an FDA 483 or Warning Letter and must complete root-cause analysis and a CAPA response within 15 business days.

Key Goal

Goal: submit a structured, verifiable response within the FDA deadline

What you get
  • Item-by-item 483 root-cause analysis (RCA) and severity grading
  • Staged timeline for the 15-business-day response
  • CAPA plan, effectiveness checks and evidence pack
  • Mock remediation rehearsal before Warning Letter escalation

21 CFR 210/211, PAI & Sterile / Data Integrity Gap Diagnosis

2-3 weeks

For finished-drug facilities facing PAI or buyer GMP audits that need clause-by-clause gap review against 210/211, sterile and Part 11 requirements.

Key Goal

Goal: see the gaps and priorities first, then drive targeted remediation

What you get
  • Gap list and priorities aligned with 21 CFR 210/211
  • Sterile (Subpart F / Annex 1) critical control point review
  • 21 CFR Part 11 and ALCOA+ data integrity assessment
  • PAI readiness document list and remediation tracker

Key Finished-Drug Regulations

Core cGMP and data integrity regulations for oral solid dose and sterile finished drugs entering the U.S. and EU.

21 CFR 210 / 211

US statutory cGMP framework for finished drugs covering production, controls, packaging, storage and release.

FDA PAI

Pre-approval inspection verifying process, data and commercial readiness.

211 Subpart F / EU Annex 1

Core requirements for sterile manufacturing environment, sterilisation and closure integrity.

21 CFR Part 11

Requirements for trustworthy electronic records and signatures — the statutory basis for data integrity.

Frequently Asked Questions

Answering common questions on PAI readiness, sterile manufacturing and 483 remediation.

Start with a 21 CFR 210/211 gap diagnosis, because PAI is grounded in cGMP compliance. Use the prioritised gaps, then prepare specifically for high-frequency PAI focus areas (process validation, data reliability).

Sustainability & ESG

Do Your Buyers Also Request ESG Evidence?

Pharma brands and manufacturers increasingly face social audits (EcoVadis, CDP, carbon footprints, human rights) alongside standard GxP/cGMP quality requirements.

Why QTC

The value of quality coaching rests on a repeatable closed-loop method, field-based coaching capability, and a clear division of work.

Four-step closed loop
1

Diagnose

Run a gap diagnosis against the target scheme and produce a gap list with priorities.

2

Build

Build the system, documents and evidence packs per the gaps.

3

Verify

Verify the system works through a mock audit / pre-audit.

4

Close

Close CAPA evidence, then re-check before the re-audit.

Coaching capability profiles

Pharma GMP (21 CFR 210/211, ICH Q7)

Coaches gap diagnosis, PAI readiness and timed 483/Warning Letter response; delivers gap lists, CAPA plans and evidence packs.

Excipients & Packaging (EXCiPACT, ISO 15378)

Coaches certification readiness, document and system build and mock audits; delivers scheme benchmark tables and pre-audit reports.

Devices & Supplements (ISO 13485, 21 CFR 111, 455-2)

Coaches QMSR implementation, 455-2 readiness and gap diagnosis; delivers gap lists and evidence packs.

Coach backgrounds

Formerly with Intertek, BV, SGS, NSF and similar bodies

5000+ · QTC Group service cases

QTC's own audit team

Audits are carried out by QTC's own team. Our auditors are experienced, several with audit backgrounds at large certification bodies; they undertake buyer-commissioned second-party audits and pre-audits and issue assessment reports.

Anonymised case

A pharmaceutical manufacturer · GMP inspection readiness

Trigger: a customer PAI was approaching, and the client's own self-inspection had flagged data integrity and deviation handling as high-risk. Work: clause-by-clause gap diagnosis against 21 CFR 210/211 and ICH Q7, SOP and record rebuild per the gaps, a full mock inspection, and item-by-item CAPA closure. Outcome: the gap list and CAPA were fully closed on schedule, the readiness evidence pack was assembled in one pass, and the formal inspection proceeded as planned.

Boundary statement

Certificates, verification statements and test reports are issued by the accredited body or laboratory that performs the work; formal audits are performed by accredited bodies, scheme owners, or the buyer's own auditors.

Preparing for PAI or a 483 Deadline?

Share your dosage form (oral solid / sterile), target market, recent inspection notice and current QMS status. QTC will assess the gaps first, then map a remediation and readiness path.

Contact QTC